Outcomes of Emergency Transcatheter Aortic Valve Replacement.


Journal

Journal of interventional cardiology
ISSN: 1540-8183
Titre abrégé: J Interv Cardiol
Pays: United States
ID NLM: 8907826

Informations de publication

Date de publication:
2019
Historique:
received: 16 06 2019
accepted: 26 08 2019
entrez: 29 11 2019
pubmed: 30 11 2019
medline: 2 4 2020
Statut: epublish

Résumé

To identify outcomes of patients undergoing emergency transcatheter aortic valve replacement (TAVR) and determine predictors of in-hospital mortality. Emergency TAVR has emerged as a viable treatment strategy for patients with decompensated severe aortic stenosis and/or regurgitation; however, data on patients undergoing emergency TAVR are limited. All emergency TAVR procedures were identified from a single tertiary academic center between January 2015 and August 2018. 31 patients underwent emergency TAVR due to cardiogenic shock (26 patients), electrical instability with incessant ventricular tachycardia (2 patients), severe refractory angina (2 patients), and decompensated heart failure with hypoxemic respiratory failure requiring mechanical ventilation (1 patient). Mechanical circulatory support (MCS) was used in 16 (51.6%). MCS initiation occurred immediately prior to TAVR in 10 patients and placed post-TAVR in 6 patients. 6 patients died before hospital discharge (in-hospital mortality 19.4%). 1-year and 2-year survival rates were 61.0% and 55.9%, respectively. Univariate predictors of in-hospital mortality were preprocedural pulmonary artery pulsatility index (PAPi) ≤1.8 (66.7% vs. 20.0%, Emergency TAVR in extreme risk patients with acute decompensated heart failure or cardiogenic shock secondary to severe aortic valve disease is associated with high in-hospital mortality rates. Careful patient selection taking into account right heart function, assessed by PAPi, and early utilization of MCS may improve survival following emergency TAVR.

Sections du résumé

OBJECTIVE OBJECTIVE
To identify outcomes of patients undergoing emergency transcatheter aortic valve replacement (TAVR) and determine predictors of in-hospital mortality.
BACKGROUND BACKGROUND
Emergency TAVR has emerged as a viable treatment strategy for patients with decompensated severe aortic stenosis and/or regurgitation; however, data on patients undergoing emergency TAVR are limited.
METHODS METHODS
All emergency TAVR procedures were identified from a single tertiary academic center between January 2015 and August 2018.
RESULTS RESULTS
31 patients underwent emergency TAVR due to cardiogenic shock (26 patients), electrical instability with incessant ventricular tachycardia (2 patients), severe refractory angina (2 patients), and decompensated heart failure with hypoxemic respiratory failure requiring mechanical ventilation (1 patient). Mechanical circulatory support (MCS) was used in 16 (51.6%). MCS initiation occurred immediately prior to TAVR in 10 patients and placed post-TAVR in 6 patients. 6 patients died before hospital discharge (in-hospital mortality 19.4%). 1-year and 2-year survival rates were 61.0% and 55.9%, respectively. Univariate predictors of in-hospital mortality were preprocedural pulmonary artery pulsatility index (PAPi) ≤1.8 (66.7% vs. 20.0%,
CONCLUSION CONCLUSIONS
Emergency TAVR in extreme risk patients with acute decompensated heart failure or cardiogenic shock secondary to severe aortic valve disease is associated with high in-hospital mortality rates. Careful patient selection taking into account right heart function, assessed by PAPi, and early utilization of MCS may improve survival following emergency TAVR.

Identifiants

pubmed: 31777471
doi: 10.1155/2019/7598581
pmc: PMC6875395
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

7598581

Informations de copyright

Copyright © 2019 Hans Huang et al.

Déclaration de conflit d'intérêts

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Références

Heart. 2018 Jan;104(1):23-29
pubmed: 28566471
N Engl J Med. 2010 Oct 21;363(17):1597-607
pubmed: 20961243
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
N Engl J Med. 2012 Oct 4;367(14):1287-96
pubmed: 22920912
N Engl J Med. 1999 Aug 26;341(9):625-34
pubmed: 10460813
J Am Coll Cardiol. 2018 Feb 27;71(8):844-856
pubmed: 29471935
JACC Cardiovasc Interv. 2018 Jun 25;11(12):1175-1185
pubmed: 29929641
EuroIntervention. 2016 Apr 20;11(13):1530-6
pubmed: 25751886
J Am Coll Cardiol. 2011 Jan 18;57(3):253-69
pubmed: 21216553
JACC Cardiovasc Interv. 2010 Nov;3(11):1150-6
pubmed: 21087751
Circulation. 1980 Jul;62(1):42-8
pubmed: 7379284
Circ J. 2018 Feb 23;82(3):874-885
pubmed: 29081473
N Engl J Med. 2011 Jun 9;364(23):2187-98
pubmed: 21639811
J Interv Cardiol. 2016 Oct;29(5):513-522
pubmed: 27550213

Auteurs

Hans Huang (H)

Division of Cardiology, Department of Medicine, University of Washington, Seattle, WA, USA.

Christopher P Kovach (CP)

Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington, WA, Seattle, USA.

Sean Bell (S)

Department of Medicine, University of Washington, Seattle, WA, USA.

Mark Reisman (M)

Division of Cardiology, Department of Medicine, University of Washington, Seattle, WA, USA.

Gabriel Aldea (G)

Division of Cardiothoracic Surgery, Department of Surgery, University of Washington, Seattle, WA, USA.

James M McCabe (JM)

Division of Cardiology, Department of Medicine, University of Washington, Seattle, WA, USA.

Danny Dvir (D)

Division of Cardiology, Department of Medicine, University of Washington, Seattle, WA, USA.

Creighton Don (C)

Division of Cardiology, Department of Medicine, University of Washington, Seattle, WA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH